tbuckley/cabot-search huggingface dataset:
Use of tumor volume as measured on F18FDG-PET/CT scan as a predictive biomarker for head and neck cancer
Authors: Y. Choi, M. Song, Y. Seol, B. Kwon, H. Shin, J. Chung, J. Lee, B. Lee, S. Kim, C. Sohn, G. Cho
Journal: Journal of Clinical Oncology (2009)

e17019 Background: Functional imaging, PET and its fusion with anatomical modalities, PET/CT promise to improve detection and characteristic disease. The objective of this study was to evaluate metabolic tumor volume as measured on F-18 FDG-PET/CT and its association with treatment response and prognosis in patients with head and neck cancer. Methods: The study population consisted of patients received neoadjuvant chemotherapy for a maximum of three cycles followed by radiation therapy. Before treatment patients were taken FDG-PET/CT scan, SUVmax, tumor volume, metastasis were recorded. Results: We enrolled 59 patients with stage III ann IV head and neck cancer. The median age was 66 years (range 47–81). There were 32 patients with stage III and 27 with stage IV. The mean SUVmax was 8.8 (range, 1.478). The mean tumor volume was 21.3 cm 3 (range, 0.2–170). There was no correlation between tumor volume and SUVmax (correlation coefficient 0.295). Higher SUVmax was not associated with an increased risk of lymph node and distant metastasis at diagnosis (p = 0.968). But higher tumor volume was associated with an increased risk of lymph node and distant metastasis at diagnosis (p = 0.063). The metabolic tumor volume as measured on PET/CT scans was predictor of treatment response and disease -free survival. The response rate were 84% (21/25) for an SUVmax &lt;5.5, 55% (19/34) for an SUVmax &gt; 5.5 (p = 0.038). The disease free survival were 31.1month for an SUVmax &lt;5.5, 4.6months for an SUVmax &gt; 5.5 (p = 0.025). Conclusions: The metabolic tumor volume as measured on F-18FDG-PET/CT is a predictive biomarker of treatment response and disease free survival for patients with head and neck cancer. No significant financial relationships to disclose.
Nutlin-3: A novel potential therapeutic in p53 wild-type ovarian carcinomas.
Authors: Erin Rebecca King, Lisa K Mullany, JoAnne S Richards, David Marc Gershenson, Kwong-Kwok Wong
Journal: Journal of Clinical Oncology (2012)

e15583 Background: Epithelial ovarian cancer (OC) is a molecularly and clinically heterogeneous disease, yet treatment is the same for all subtypes. Type I carcinomas, including low grade serous, mucinous, clear cell, and endometrioid OCs, are relatively chemoresistant. In contrast, Type II or high grade serous OCs are more aggressive yet responsive to chemotherapy. Molecularly, 96% of high grade serous OCs harbor p53 mutations, whereas Type I carcinomas are more frequently p53 wild-type. Nutlin-3 is a novel therapeutic which inhibits MDM2, activates wild-type p53, and induces apoptosis. We therefore sought to validate nutlin-3 as a therapeutic compound for p53 wild-type OCs. Methods: Two low grade serous, 2 clear cell, 2 endometrioid, 3 mucinous, and 4 high grade serous OC cell lines were treated with varying concentrations of nutlin-3, and proliferation assays were performed. A p53-null cell line was used as a negative control. The cells were then treated with nutlin-3 at their IC50s, and qRT-PCR and Western blot (WB) quantified MDM2, p53, and p21 expression at 24, 48, and 72 hours after treatment. The cell lines were sequenced for p53 mutations in exons 5-8. Results: Responses to nutlin-3 were variable and dependent on p53 mutation status. Low grade and clear cell lines were most sensitive to nutlin-3, endometrioid type were intermediately sensitive, and mucinous were resistant. Two of the four high grade cell lines were sensitive to nutlin-3, both of which were p53 wild-type. Endometrioid and low grade serous cell lines possessing heterozygous p53 mutations were still more sensitive than the p53-null cell line. On qRT-PCR and WB, levels of p53 were decreased after nutlin-3 treatment and were absent in the p53-null cell line. MDM2 and p21 were initially upregulated in sensitive cell lines, but returned to near-baseline levels after 72 hours. In the more resistant cell lines, p21 induction was reduced or absent. Conclusions: Nutlin-3 is a novel potential therapeutic agent for p53 wild-type ovarian carcinoma, and is dependent on an intact p53 pathway with p21 upregulation. Even OC cell lines with heterozygous p53 mutation responded modestly to nutlin-3 treatment. Further investigation of nutlin-3 treatment in ovarian cancer is warranted.
CARDIAC PNEUMONIA: ACUTE MITRAL REGURGITATION AS A RARE CAUSE OF RIGHT UPPER LUNG LOBE INFILTRATE
Authors: Mohammad Khalid Mojadidi, Ninel Hovnanians, Osama Alsara, Ahmed Mahmoud, Nayan Agarwal, Sanaullah Mojaddedi, R. David Anderson
Journal: Journal of the American College of Cardiology (2017)
Multicenter, randomized, controlled, open-label study of bevacizumab combined with carboplatin and paclitaxel versus carboplatin and paclitaxel in patients with metastatic nasopharyngeal carcinoma.
Authors: Li Zhang, Yan Huang, Tao Qin, Hongyun Zhao, Likun Chen, Peiyu Huang, Xue Hou, YuanYuan Zhao, Wenfeng Fang, Yuxiang Ma, Yunpeng Yang, Ting Zhou, Zhihuang Hu, Shaodong Hong
Journal: Journal of Clinical Oncology (2014)

TPS6100 Background: Nasopharyngeal carcinoma (NPC) is an endemic disease with a high incidence in South-East Asian. Standard chemotherapy for metastatic NPC is platinum-based regimen. Improvement the outcome of mNPC patients remains a high-unmet medical need. Vascular endothelial growth factor (VEGF) was over expressed in 67% of NPCs and correlated to higher rate of recurrence and less survival. Bevacizumab, an anti-tumor angiogenesis monoclonal antibody, precisely targets VEGF to inhibit angiogenesis for continuous tumor control. A phase II multi-institutional trial (RTOG0615) showed that bevacizumab plus chemoradiation is feasible, and might delay the progression of subclinical distant disease in NPC. We plan to initiate the first randomized study to evaluate the efficacy and safety of bevacizumab plus paclitaxel/carboplatin (TC) particularly in mNPC population. Methods: This is a multi-center, randomized phase II study. The primary end-point of the study was progression-free survival (PFS) based on independently assessment. Secondary end-point include overall survival (OS), response rate (ORR), disease control rate (DCR), health-related quality of life (HRQoL) and toxicity profiles. The study was designed to have 60% power to detect a 33% improvement of PFS in bevacizumab treated arms (from 6 month to 9 month) at a two-sided significance level of 5%. Based on these assumptions, a total of 80 patients are needed to observe 57 events. Eighty treatment naïve metastatic NPC patients will be randomly assigned (1:1) to receive TC plus bevacizumab or TC alone. TC consisted of carboplatin (AUC 5, iv) /paclitaxel (175 mg/kg, iv) on day 1 of each 3-week cycle for up to 6 cycles; bevacizumab (7.5 mg/kg, iv) was administered with carboplatin/paclitaxel on day 1 and maintenance after the finish of chemotherapy until disease progression or unacceptable toxicity. Recruitment will begin in March 2014. The duration of the trial will be 24 months (12 months recruitment and 12 months follow-up).
COMBINED PREBIOTICS AND PROBIOTICS TREATMENT IS NOT SUPERIOR TO SINGLE REGIMEN FOR CARDIOPROTECTION IN OBESE-INSULIN RESISTANT RATS
Authors: Nipon Chattipakorn, Wannipa Tunapong, Sakawduen Yasom, Keerati Wanchai, Titikorn Chunchai, Pongpan Tanajak, Nattayaporn Apaijai, Parameth Thiennimitr, Sasithorn Sirilun, Chaiyavat Chaiyasut, Anchalee Pongchaidecha, Anusorn Lungkapin, Wasana Pratchayasakul, Siriporn Chattipakorn
Journal: Journal of the American College of Cardiology (2017)
UMBILICAL ARTERIAL BLOOD FLOW IN THE THIRD TRIMESTER AND ITS ASSOCIATION WITH CLINICAL AND NEURODEVELOPMENTAL OUTCOMES IN CHILDREN WITH CRITICAL NEONATAL CONGENITAL HEART DISEASE
Authors: Jayani Abeysekera, Dora Gyenes, Charlene Robertson, Gwen Alton, Irina Dinu, Dianne Creighton, Joseph Atallah, Ivan Rebeyka, Lisa Hornberger
Journal: Journal of the American College of Cardiology (2017)
IMPACT OF MALIGNANT LEFT VENTRICULAR HYPERTROPHY ON INCIDENT ASYMPTOMATIC LEFT VENTRICULAR DYSFUNCTION: THE MESA STUDY
Authors: Matthew N. Peters, Stephen Seliger, Susie Hong-Zohlman, Robert Christenson, James de Lemos, Joao Lima, Alain Bertoni, Lori Daniels, Christopher DeFilippi
Journal: Journal of the American College of Cardiology (2017)
Long-Term Outcome Following B-Cell Depletion Therapy with Rituximab In Children and Adults with Immune Thrombocytopenia (ITP)
Authors: Vivek L. Patel, Matthieu Mahévas, Roberto Stasi, Susanna Cunningham-Rundles, Bertrand Godeau, Soo Y. Lee, Julie Kanter, Ellis J. Neufeld, Tillmann Taube, Ugo Ramenghi, Shalini Shenoy, Mary J. Ward, Nino Mihatov, Vinay L. Patel, Philippe Bierling, Nichola Cooper, James B. Bussel
Journal: Blood (2010)
EFFECTS OF CANAGLIFLOZIN VERSUS GLIMEPIRIDE ON INFLAMMATORY BIOMARKERS AND CHEMOKINES IN PATIENTS WITH TYPE 2 DIABETES MELLITUS
Authors: Luc Van Gaal, Tim Garvey, Lawrence Leiter, Ujjwala Vijapurkar, James List, Robert Cuddihy, Jimmy Ren, Michael Davies
Journal: Journal of the American College of Cardiology (2017)
Oral topotecan and intravenous carboplatin with G-CSF support in previously treated patients with extensive stage small cell lung cancer: A phase II trial of the North Central Cancer Treatment Group
Authors: J. Jett, B. I. Mattar, S. L. Hillman, J. Kugler, J. C. Michalak, A. A. Adjei, E. Johnson
Journal: Journal of Clinical Oncology (2004)

7203 Intravenous (IV) topotecan (T) has been shown to have activity against small cell lung cancer (SCLC). Goal: To evaluate response rate and toxicity of oral T and IV carboplatin (C) with G-CSF support in extensive stage disease (ED) SCLC and follow patients for survival. Methods: Patients were 18 years or older, had histologic proof of SCLC, extensive stage, measurable disease, PS 0, 1 or 2, and met hematologic and blood chemistry parameters. All patients were previously untreated. Treatment was oral T (1.75 mg/m2/daily x5) and C (AUC=6) on day 5 with G-CSF (5 μg/kg) daily x10. Patients were treated every 21 days for a maximum of 6 cycles. The planned accrual was 39, but the trial was stopped early due to toxicity. Results: 26 eligible patients were treated. The median age was 63 (range 44–78), 62% were females and 85% were PS 0 or 1. One patient had prior whole brain RT and one had prior palliative RT. 46% of patients had ≥ 2 metastatic sites. The median number of cycles received was 4. A partial response was observed in 16 patients (62%) (95% CI 41–80). The median TTP was 5.9 months with a 1-year progression free survival of 15% (95%CI 5–47%). The median survival was 11.8 months with 46% one-year survival (95%CI 30–70%). Seven patients are still alive. There were 3 deaths due to low ANC with infection and one sudden death due to a CV event that was possibly related to treatment. Grade 3+ hematologic adverse events occurred in 85% with 2 G3 febrile neutropenia, G4 neutropenia in 23% and G4 thrombocytopenia in 19%. G3+ non-heme adverse events occurred in 54%. G3–4 dyspnea, diarrhea and vomiting occurred in 3 patients each (11.5%). Conclusion: Oral topotecan and carboplatin (IV) has reasonable activity against SCLC. This schedule was associated with unacceptable toxicity. New therapies with novel agents need to be explored. No significant financial relationships to disclose.
A phase II study of suberoylanilide hydroxamic acid (SAHA) in subjects with locally advanced, recurrent, or metastatic adenoid cystic carcinoma (ACC).
Authors: Priscila Hermont Goncalves, Shivaani Kummar, Lillian L. Siu, Aaron Richard Hansen, Panayiotis Savvides, Ammar Sukari, Joseph Chao, Lance K. Heilbrun, Mary Jo Pilat, Daryn W. Smith, Lindsay Casetta, Scott Anthony Boerner, Patricia LoRusso
Journal: Journal of Clinical Oncology (2013)

6045 Background: SAHA is a small molecule inhibitor of histone deacetylases (HDAC). Based on confirmed responses noted in 2 ACC patients treated with SAHA at our institution; we initiated this phase II trial. Methods: Patients with LA, recurrent or metastatic ACC and adequate organ function were eligible. Any prior number of chemotherapy regimens was allowed. Tumor tissue and blood were collected for correlative studies. SAHA was administered orally 400 mg daily for 28 days. The primary objective was to evaluate response rate (RR). Secondary endpoints included: time to tumor response (TTR); response duration (RD); progression-free survival (PFS); overall survival (OS); and adverse events (AE). 29 evaluable patients were needed in a Simon 2-stage optimal design to distinguish RR of at most 5% vs. at least 20%, with alpha = 0.15 and power = 0.90. Results: 30 evaluable patients (overenrolled by 1) were accrued from at 5 different centers between August 2010 and June 2012. Median follow up among the censored patients is 3.8 months for PFS, and 7.2 months for OS. 19 patients were female, 24 were Caucasian, median age was 53 years (range 21-73); 21 patients had a performance status of 1; 20 patients were chemo-naïve. The median number of cycles completed was 5 (range 1-27+). Lymphopenia (n=5), hypertension (n=3), oral pain (n=2), thromboembolic events (n=2) and fatigue (n=2) were the only grade 3 AEs that occurred in more than 1 patient. 5 patients were dose reduced due to AEs. At the time of data cut-off, 9/30/2012, 1 patient with lung metastasis had a PR, with RD of 11.2+ months. TTR was 7.7 months. SD was the best response in 25 patients. Median PFS is 12.7 months (90% confidence interval lower limit: 3.7 months). Median OS has not been reached. There were 6 patients with PFS &gt; 1 year. The correlative studies results will be presented. Conclusions: SAHA shows promise in the treatment of ACC. We are awaiting genomic analysis of the tumors to study the basis of clinical benefit (PR and SD) of SAHA in ACC. Future drug combination studies in ACC are being considered focusing on the epigenetic mechanism of SAHA. Supported by 5U01CA062487/19. Clinical trial information: NCT01175980.
EVALUATION OF HEMOCONCENTRATION BASED BIOELECTRICAL VECTORIAL IMPEDANCE ANALYSIS IS USEFUL RISK STRATIFICATION IN ACUTE DECOMPENSATED HEART FAILURE
Authors: Yoshiyuki Yazaki, Norihiro Kogame, Hiroki Niikura, Masahide Tokue, Nobutaka Ikeda, Raisuke Iijima, Hidehiko Hara, Masao Moroi, Masato Nakamura
Journal: Journal of the American College of Cardiology (2017)
Effect of clinical NGS-based cancer genomic profiling on physician treatment decisions in advanced solid tumors.
Authors: Fadi S. Braiteh, Jeff Porter Sharman, Donald A. Richards, Matthew Rama Skelton, Linda Cheryl DeMarco, Sasha Vukelja, Ian Schnadig, Sharon Wilks, Christopher A. Yasenchak, Jerome H. Goldschmidt, Regina Resta, Stephen Lane Richey, John W. Smith, Lina Asmar, Yunfei Wang, Ann Morcos, Tracy Locke, Yali Li, Gary A. Palmer
Journal: Journal of Clinical Oncology (2014)

11109 Background: Next generation sequencing (NGS) of routinely fixed tissue from pts with advanced solid tumors may inform treatment planning. Foundation Medicine has developed a CLIA-certified, CAP-accredited test (FoundationOne, F1) to simultaneously characterize all 4 classes of genomic alterations in 236 (originally 182) cancer genes. Primary study objective was to determine how many physicians would change treatment approach based on F1 results (switch rate=SR). An exploratory objective was to compare PFS impact of any switches. Methods: This was a prospective, multicenter, single-arm trial in pts with refractory metastatic solid tumors of any type. Eligible pts must have been receiving second- or third-line therapy (first-line for pancreatic) and were initially registered within 10 weeks of beginning a regimen and before response assessment reimaging. Tumors were assayed with F1 after initial registration. Upon progression and documentation of next proposed therapy, they were re-registered and results of F1 were provided to doctors. If F1 caused a change in proposed therapy, a switch was recorded. Results: 233 pts were eligible; 103 were not re-registered (pt died, investigator decision, withdrew consent). Two questionnaires were missing; 128 pts were included in this analysis. Median age 61 yrs; female (65.6%). Tumor types mainly included breast (20%), lung (16%), and colon (13%). The SR was 28.1% (36 switch, 92 no switch). For 95 treated pts, the SR was 27.4% (26 received switch drug, 69 received initial recommendation; [33 pts did not receive Rx due to PD, death, hospice, or pt decision]). All of the major tumor types above had switch rates above 20%. In 77% of nonswitch cases, physicians reported that there were “not enough” treatment options available. Data collection for PFS analysis and correlation of results to tumor genomic profiles are ongoing. Conclusions: Comprehensive NGS-based profiling resulted in altered therapeutic choice in 28% of advanced solid tumor patients in the community setting, highlighting the current broad applicability of this approach. As more targeted therapeutics advance to larger trials and become approved, the impact of comprehensive testing may be expected to increase.
EARLY CORONARY ANGIOGRAPHY IN PATIENTS WITH OUT-OF-HOSPITAL CARDIAC ARREST WITHOUT ST-ELEVATION MYOCARDIAL INFARCTION: A META-ANALYSIS OF 1,460 PATIENTS
Authors: Paul A. Gurbel, Rahul Chaudhary, Kevin Bliden, Harleen Dehal, Udaya Tantry
Journal: Journal of the American College of Cardiology (2017)
Genetic Profiling of Myeloproliferative Disorders by Single Nucleotide Polymorphism Oligonucleotide Microarray.
Authors: Norihiko Kawamata, Seishi Ogawa, Ross L. Levine, Yana Pikman, Toshiki Nanya, Masashi Sanada, Carl W. Miller, D. Gary Gilliland, H. Phillip Koeffler
Journal: Blood (2006)
LETS PUT THE TRIALS TO A TEST: A 23 YEAR REVIEW OF UNITED STATES FOOD AND DRUG ADMINISTRATION (FDA) RECORDS OF CARDIOVASCULAR DISEASE CLINICAL TRIALS
Authors: Odunayo Olorunfemi, Gbolahan Ogunbayo, Amole Ojo, Rebecca Ojo, Olatunde Ola
Journal: Journal of the American College of Cardiology (2017)
SERIAL ASSESSMENT OF HEART RATE AND BETA BLOCKER USE IN CHRONIC HEART FAILURE PATIENTS WITH REDUCED EJECTION FRACTION IN A LARGE INTEGRATED HEALTHCARE NETWORK
Authors: Hanna Kim Gaggin, Alexander Turchin, Harshali Patel, Yang Song, April Trebnick, Gheorghe Doros, Nasrien Ibrahim, Juan Maya, Christopher Cannon, James Januzzi
Journal: Journal of the American College of Cardiology (2017)
AGE AND THE EFFECTIVENESS OF RISK STRATIFICATION AND DIAGNOSTIC THRESHOLDS FOR MYOCARDIAL INFARCTION WITH HIGH-SENSITIVITY CARDIAC TROPONIN
Authors: Atul Anand, Andrew Chapman, Anoop Shah, Philip Adamson, Amy Ferry, Dennis Sandeman, Fiona Strachan, David Newby, Nicholas Mills
Journal: Journal of the American College of Cardiology (2017)
Spring budget: cash for social care and a green paper on future funding
Authors: Chris Ham, Richard Humphries
Journal: BMJ (2017)

The government has bought some time to find a sustainable solution

The spring budget delivered £2bn of new funding for social care over three years from 2017‑18 and a commitment to publish a green paper outlining options for future funding. The government’s decision to find additional resources reflects the huge pressures facing social care in England, which the Care Quality Commission described as near “tipping point,”1 and the effect of these pressures on the NHS. These resources will go some way towards stabilising social care, even though they fall short of the sums independent commentators have argued are needed to bridge the expected funding gap by the end of this parliament.2

The announcement of a green paper, planned for the autumn, fulfils the prime minister’s commitment to explore ways of making the funding of social care sustainable. Several options are likely to be considered, including compulsory social insurance as used in countries such as Germany and Japan; acting on the recommendations of the Dilnot report to introduce a cap on care costs, which was included in the Care Act …
VALIDEZ DIAGNÓSTICA DE LA CLASIFICACIÓN NICE PARA PREDECIR INVASIÓN PROFUNDA DE LA SUBMUCOSA EN LOS PÓLIPOS DEL COLON
Authors: I Puig, M López-Cerón, A Herreros De Tejada, M Pellisé, N Ascón, L De Castro, J López, P Vega, Ó Nogales, P Díez, M Hernández-Conde, Á Ferrández, AZ Gimeno, G De La Poza, L Rivero, A Burgos, E Martínez-Bauer, J Mendoza, MA Álvarez, B Peñas, F Vida
Journal: Endoscopy (2015)

La clasificación NICE propone unos criterios endoscópicos para predecir invasión profunda de la submucosa en los pólipos del colon. Estos criterios podrían ayudar a decidir con mayor seguridad el tratamiento más adecuado (endoscópico o quirúrgico).
The Novel Bispecific Diabody αCD40/αCD28 Strengthens Leukemic Dendritic Cell Induced T Cell Reactivity.
Authors: Ilse Houtenbos, Saskia J.A.M. Santegoets, Theresia M. Westers, Quinten Waisfisz, Sergey Kipriyanov, Fedor Denkers, Rik J. Scheper, Tanja D. de Gruijl, Gert Ossenkoppele, Arjan A. van Loosdrecht
Journal: Blood (2006)
Cosmic Mutational Analysis in Suspected Myeloproliferative Neoplasms Using Next Generation Sequencing with a Fifty Gene Panel
Authors: Swachi Jain, Ritesh Sachdev, Pranav Dorwal, Simmi Mehra, Smeeta Gajendra, Dharmendra Jain, Shalini Goel, Nitin Sood, Vimarsh Raina
Journal: Blood (2015)
The role of BMI and age in chemotherapy-induced amenorrhea (CIA) in premenopausal breast cancer (PBC) patients treated with adjuvant FEC100 with or without docetaxel (D).
Authors: Monica Verrico, Luigi Rossi, Federica Tomao, Erika Giordani, Eleonora Zaccarelli, ANSELMO PAPA, Martina Strudel, Giulia Rinaldi, Francesca Perrone-Congedi, Davide Caruso, Gian Paolo Spinelli, Carlo Capalbo, Giuseppe Lo Russo, Salvatore Evangelista, Loredana Bianchi, Valeria Stati, Alessandra Anna Prete, Silverio Tomao
Journal: Journal of Clinical Oncology (2014)

e12000 Background: Transitory or definitive amenorrhea (A) is a related side effect, specifically affecting young women diagnosed with breast cancer and treated with adjuvant chemotherapy (CT). Premature ovarian failure (POF) is often related to increased morbidity and mortality for heart disease and osteoporosis. In this study we analyzed the incidence of CIA in PBC patients and the correlation between their BMI and occurrence of A. Methods: 32 PBC patients, median age 44, were treated with adjuvant FEC±D. BMI was evaluated in all women. At accrual all the pts had normal menstrual activity (MA) and nobody received concomitant endocrine therapy. Results: 18 patients received FEC and 14 patients received FEC+D. In 27 patients A occurred during CT: in 89% of pts with FEC and 86% with FEC+D. In 62% of pts A occurred within first three cycles of CT. CIA occurred within the first two doses in 15/32 pts: in 44% treated with FEC and 50% with FEC+D. MA reappeared at the end of CT in 12% of pts (median age 44 years). 72% of pts had BMI<24.9 and 28% >25. In FEC group 14 pts had BMI<24.9 (61% experienced A) and 4 BMI>25 (100% experienced A); MA reappeared in 2 patients (43 and 44 ys), both with BMI<24.9. In FEC+D group 9 pts had BMI<24.9 (50% experienced A) and 5 had BMI>25 (100% experienced A); MA reappeared in 2 pts (35 and 47 years; 1 patient with BMI<24.9 and another with BMI>25). Conclusions: Our small experience showed that A occurs very frequently during FEC±D and that age is the strongest predictor for A occurrence. There was no difference in the incidence of CIA between the 2 subgroups of treatment. No correlation was observed between BMI and appearance of A.